drugset / Trial / NCT04818216
Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection
Phase 2
Completed
28 enrolled
The University of Texas Health Science Center at San Antonio
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
An interventional clinical trial using oral nicotinamide riboside (NR) in hospitalized patients with COVID-19 infection and acute kidney injury to determine the effect of NR on whole blood nicotinamide adenine dinucleotide (NAD+) levels and to evaluate safety of the use of NR.
Timeline
- Start
- 2021-06-11
- Primary completion
- 2021-12-09
- Completion
- 2022-01-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nicotinamide riboside | Small molecule | 250 mg | Oral |